AAM Statement on Considered Expansion of Antitrust Lawsuit Against Generic Drugmakers | Association for Accessible Medicines
Stop REMS Abuse - Anti-competitive practices are costing patients billions - you can help!

AAM Statement on Considered Expansion of Antitrust Lawsuit Against Generic Drugmakers

WASHINGTON, DC (October 31, 2017) – AAM and our member companies are committed to supporting policies that promote competition and help speed the availability of generic and biosimilar medicines to patients.

AAM is fully committed to compliance with all laws and ethical business practices.

Attribution: Jeff Francer, Senior Vice President and General Counsel

MEDIA CONTACT:
Rachel Schwartz 
202.249.7147 (o)
202.251.8881 (c)